Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511401 · ClinicalTrials.gov registry record · NA
Informing Pain Treatment Using Pharmacogenomic Analysis
A NA study of Adult Patients Who Are Receiving Oncologic Care, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT06511401 is a NA study of Adult Patients Who Are Receiving Oncologic Care that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 800 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06511401, a NA study of Adult Patients Who Are Receiving Oncologic Care, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Conditions Studied
Interventions
- OTHER Pharmacogenomic (PGx) results.
Study Locations (1)
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06511401
The ClinicalTrials.gov registry entry for NCT06511401 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult Patients Who Are Receiving Oncologic Care appearing as the primary indexed condition, and to 1 intervention - of which Pharmacogenomic (PGx) results. is the first listed.
NCT06511401 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06511401 about?
NCT06511401 is a clinical study titled "Informing Pain Treatment Using Pharmacogenomic Analysis". This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
What is the current status of trial NCT06511401?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2024-07-30. Estimated completion is 2028-03-31.
What conditions does trial NCT06511401 study?
This clinical trial studies the following conditions: Adult Patients Who Are Receiving Oncologic Care.
What interventions are being tested in trial NCT06511401?
The interventions under investigation include: Pharmacogenomic (PGx) results. (OTHER).
Who is sponsoring clinical trial NCT06511401?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06511401 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.